Advertisement

---

PERRIGO COMPANY

Perrigo Company Acquires Ophthalmic Product Portfolio From Fera Pharmaceuticals, LLC For An Upfront Payment Of $93 Million

[2013-06-17] - - Expands Perrigo's Rx extended topical portfolio to include ophthalmic sterile ointment and solution products with the addition of nine ANDAs
- Upfront cash payment of $93 million plus potential contingent payments totaling $36 million, certain of which relate to additional product rights; Perrigo expected to receive tax benefit of approximately $20 million
- Portfolio generated more than $30 million in net revenues during the year ended December 31, 2012
- The acquisition is anticipated to be more than $0.12 accretive to adjusted EPS and more than $0.04 accretive to GAAP EPS in fiscal year 2014 and immediately accretive to ROIC hurdles


Perrigo Announces FDA Final Approval For Generic Equivalent To Sanctura XR®

[2013-05-29] -


Perrigo Confirms Patent Challenge For Generic Version Of Axiron® Topical Solution

[2013-05-29] -


Perrigo To Transfer Common Stock Listing To NYSE

[2013-05-23] -


Perrigo Launches First-Ever Industry Marketing Campaign For Store Brand OTC Medications

[2013-05-13] -


Advertisement
Most read: scientific news

More:

---


---
Follow us...

google plus Facebook twitter Newsletter

---


---

Plan du site

Actualités

Actualités

Actualités

Réglementaire

Emploi

Annuaires

Dictionnaire

Divers